HCID 10116462、化合物 → HCID 86584947、化合物
反応式
C(OC([N:8]1[CH2:13][CH2:12][CH:11]([C:14](=[O:33])[NH:15][C:16]2[S:17][C:18]3[C:24]([N:25]4[CH2:30][CH2:29][O:28][CH2:27][CH2:26]4)=[CH:23][CH:22]=[C:21]([O:31][CH3:32])[C:19]=3[N:20]=2)[CH2:10][CH2:9]1)=O)(C)(C)C>FC(F)(F)C(O)=O>[CH3:32][O:31][C:21]1[C:19]2[N:20]=[C:16]([NH:15][C:14]([CH:11]3[CH2:10][CH2:9][NH:8][CH2:13][CH2:12]3)=[O:33])[S:17][C:18]=2[C:24]([N:25]2[CH2:26][CH2:27][O:28][CH2:29][CH2:30]2)=[CH:23][CH:22]=1参加物
3
実験手順
4-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-ylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester (95 mg, 0.2 mmol) were dissolved in trifluoroacetic acid (0.8 ml). After 1 h at room temperature, the mixture was evaporated to dryness. Purification as described for tetrahydro-pyran-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide afforded the title compound as a white solid (77%), MS: m/e=377(M+H+).
後処理
- customthe mixture was evaporated to dryness
- customPurification